Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liposic EDO Gel + hyaluronic acid is a combination ophthalmic product used primarily for the symptomatic treatment of dry eye syndrome. The formulation combines carbomer-based gel (as in Liposic EDO Gel) with hyaluronic acid. Carbomer acts as a lubricant and tear substitute, forming a highly viscous protective layer over the ocular surface to maintain moisture and relieve symptoms such as dryness, irritation, burning, or tiredness of the eyes[1][2][3]. Hyaluronic acid is a naturally occurring glycosaminoglycan that enhances hydration by retaining water on the ocular surface and may promote healing and comfort[5][10]. This combination targets multiple layers of the tear film—aqueous, mucin, and lipid—to provide comprehensive relief for patients with refractory or severe dry eye symptoms[4]. The product is suitable for long-term use in cases where natural tear production is insufficient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Liposic EDO Gel + hyaluronic acid.